Health
Intracranial Responses Are Induced With Entrectinib in NTRK+ Tumors – Targeted Oncology
Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
Patients with NTRK fusionpositive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib (Rozlytrek), according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
In this analysis of patients with NTRK fusion-positive, TRK inhibitor-naïve solid tumors treated with entrectinib, the intracranial objective response rate (ORR) was 50% in all patients with baseline metastases and median intracranial duration of resp…
-
Noosa News14 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News22 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common
-
Noosa News23 hours agoCountdown on for Noosa Eat & Drink Festival 2025